Evaluation of Migraine Management Mobile App Combined With Electrophysiological Measurements for Identification of Migraine Attack Risk and Beneficial Preventive Actions.
Not Applicable
- Conditions
- Migraine
- Registration Number
- NCT03083860
- Lead Sponsor
- Brainmarc Ltd.
- Brief Summary
Evaluation of migraine management mobile app combined with electrophysiological measurements for identification of migraine attack risk and beneficial preventive actions.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
- Diagnosed with migraine by a neurologist.
- Male or Female, aged 18 -50 years.
- Having 3-10 migraine attacks per month.
- Able and willing to comply with all study requirements.
- Having Android based smartphone
Exclusion Criteria
- Diagnosed with chronic pain, neurological or psychiatric disorders.
- Current or past use of anti-depressants.
- A user of recreational or illicit drugs or has had a recent history of drug or alcohol abuse or dependence.
- History of seizures.
- Head injury with consciousness loss in the last three months.
- Diagnosed as ADHD and/or use of Ritalin.
- Hearing disorder and/or known eardrum impairment.
- Having migraine attacks occurring only during the menstruation.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Evaluation of correlation of attention-related electrophysiological changes and patients' migraine dynamics based at-home EEG measurements via mobile phone app. 12 months significant difference between interictal days and treictal days
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What electrophysiological biomarkers does the Brainmarc Ltd. migraine app use to predict attack risk?
How does the BEI device in NCT03083860 compare to CGRP inhibitors in migraine preventive efficacy?
Do cortical excitability or autonomic nervous system metrics correlate with app-based migraine risk stratification?
What adverse events are associated with transcutaneous electrical neurostimulation (TENS) in migraine management?
How might wearable electrophysiological monitoring advance personalized migraine prevention strategies?
Trial Locations
- Locations (1)
Rambam MC
🇮🇱Haifa, Israel
Rambam MC🇮🇱Haifa, IsraelDavid Yarnitzki, MD, Prof.Contact972-47772605